In the past week, CARA stock has gone up by 2.87%, with a monthly decline of -18.08% and a quarterly surge of 30.73%. The volatility ratio for the week is 9.92%, and the volatility levels for the last 30 days are 10.33% for Cara Therapeutics Inc The simple moving average for the past 20 days is -9.80% for CARA’s stock, with a -49.06% simple moving average for the past 200 days.
Is It Worth Investing in Cara Therapeutics Inc (NASDAQ: CARA) Right Now?
CARA has 36-month beta value of 0.78. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CARA is 46.46M, and currently, short sellers hold a 5.55% ratio of that float. The average trading volume of CARA on April 23, 2024 was 655.83K shares.
CARA) stock’s latest price update
Cara Therapeutics Inc (NASDAQ: CARA)’s stock price has increased by 10.50 compared to its previous closing price of 0.66. However, the company has seen a 2.87% increase in its stock price over the last five trading sessions. MarijuanaStocks reported 2024-04-02 that Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with BofA Securities repeating the rating for CARA by listing it as a “Underperform.” The predicted price for CARA in the upcoming period, according to BofA Securities is $6 based on the research report published on March 08, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see CARA reach a price target of $20, previously predicting the price at $17. The rating they have provided for CARA stocks is “Overweight” according to the report published on March 08th, 2022.
Canaccord Genuity gave a rating of “Buy” to CARA, setting the target price at $33 in the report published on November 01st of the previous year.
CARA Trading at -9.90% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.36% of loss for the given period.
Volatility was left at 10.33%, however, over the last 30 days, the volatility rate increased by 9.92%, as shares sank -17.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.43% upper at present.
During the last 5 trading sessions, CARA rose by +2.87%, which changed the moving average for the period of 200-days by -71.80% in comparison to the 20-day moving average, which settled at $0.8021. In addition, Cara Therapeutics Inc saw -1.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CARA starting from Terrillion Scott, who sale 2,753 shares at the price of $0.83 back on Apr 05 ’24. After this action, Terrillion Scott now owns 88,247 shares of Cara Therapeutics Inc, valued at $2,285 using the latest closing price.
Goncalves Joana, the CHIEF MEDICAL OFFICER of Cara Therapeutics Inc, sale 2,753 shares at $0.83 during a trade that took place back on Apr 05 ’24, which means that Goncalves Joana is holding 53,365 shares at $2,285 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -5.75 for the present operating margin
- 0.7 for the gross margin
The net margin for Cara Therapeutics Inc stands at -5.61. The total capital return value is set at -1.2. Equity return is now at value -109.80, with -76.94 for asset returns.
Based on Cara Therapeutics Inc (CARA), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -2.48. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 316.61.
Currently, EBITDA for the company is -121.24 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.47. The receivables turnover for the company is 5.22for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.
Conclusion
To put it simply, Cara Therapeutics Inc (CARA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
